Show simple item record

dc.contributor.authorCassidy, JW
dc.contributor.authorBatra, AS
dc.contributor.authorGreenwood, W
dc.contributor.authorBruna, A
dc.date.accessioned2020-08-04T13:57:46Z
dc.date.issued2016-12
dc.identifier.citationEndocrine-related cancer, 2016, 23 (12), pp. T259 - T270
dc.identifier.issn1351-0088
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3893
dc.identifier.eissn1479-6821
dc.identifier.doi10.1530/erc-16-0251
dc.description.abstractDespite remarkable advances in our understanding of the drivers of human malignancies, new targeted therapies often fail to show sufficient efficacy in clinical trials. Indeed, the cost of bringing a new agent to market has risen substantially in the last several decades, in part fuelled by extensive reliance on preclinical models that fail to accurately reflect tumour heterogeneity. To halt unsustainable rates of attrition in the drug discovery process, we must develop a new generation of preclinical models capable of reflecting the heterogeneity of varying degrees of complexity found in human cancers. Patient-derived tumour xenograft (PDTX) models prevail as arguably the most powerful in this regard because they capture cancer's heterogeneous nature. Herein, we review current breast cancer models and their use in the drug discovery process, before discussing best practices for developing a highly annotated cohort of PDTX models. We describe the importance of extensive multidimensional molecular and functional characterisation of models and combination drug-drug screens to identify complex biomarkers of drug resistance and response. We reflect on our own experiences and propose the use of a cost-effective intermediate pharmacogenomic platform (the PDTX-PDTC platform) for breast cancer drug and biomarker discovery. We discuss the limitations and unanswered questions of PDTX models; yet, still strongly envision that their use in basic and translational research will dramatically change our understanding of breast cancer biology and how to more effectively treat it.
dc.formatPrint-Electronic
dc.format.extentT259 - T270
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectAnimals
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectMammary Neoplasms, Experimental
dc.subjectAntineoplastic Agents
dc.subjectXenograft Model Antitumor Assays
dc.subjectNeoplasm Transplantation
dc.subjectFemale
dc.subjectDrug Discovery
dc.subjectPrecision Medicine
dc.titlePatient-derived tumour xenografts for breast cancer drug discovery.
dc.typeJournal Article
dcterms.dateAccepted2016-10-04
rioxxterms.versionofrecord10.1530/erc-16-0251
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEndocrine-related cancer
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Preclinical Modelling of Paediatric Cancer Evolution
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Preclinical Modelling of Paediatric Cancer Evolution
pubs.publication-statusPublished
pubs.volume23
pubs.embargo.termsNot known
icr.researchteamPreclinical Modelling of Paediatric Cancer Evolutionen_US
dc.contributor.icrauthorBruna Cabot, Alejandraen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0